Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 clinical trial of IC-100

Next Previous
X
Search
Trial Profile

A phase 1/2 clinical trial of IC-100

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IC 100 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; First in man; Therapeutic Use

    • Most Recent Events

    • 05 May 2021 According to an IVERIC bio media release, the Company now believes that IC-100 will likely be delayed from entering into a Phase 1/2 clinical trial this year.
    • 09 Mar 2021 New trial record
    • 03 Mar 2021 According to an IVERIC bio media release, company is preparing an IND for IC-100 and plans to meet with regulatory authorities to discuss its selected doses for a first-in-human clinical trial prior to the submission. The Company plans to file an IND for IC-100 with the FDA and begin enrolling patients in this trial in the second half of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top